JP4056887B2 - １−オキサ−３，９−ジアザ−スピロ［５．５］ウンデカン−２−オン誘導体およびそのニューロキニン受容体拮抗剤としての使用 - Google Patents

１−オキサ−３，９−ジアザ−スピロ［５．５］ウンデカン−２−オン誘導体およびそのニューロキニン受容体拮抗剤としての使用 Download PDF

Info

Publication number
JP4056887B2
JP4056887B2 JP2002589488A JP2002589488A JP4056887B2 JP 4056887 B2 JP4056887 B2 JP 4056887B2 JP 2002589488 A JP2002589488 A JP 2002589488A JP 2002589488 A JP2002589488 A JP 2002589488A JP 4056887 B2 JP4056887 B2 JP 4056887B2
Authority
JP
Japan
Prior art keywords
compound
formula
diaza
oxa
spiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002589488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534758A5 (https=
JP2004534758A (ja
Inventor
ツァイ，ハイ−イン
ディロン，マイケル・パトリック
ガレイ，グウィード
ゴーグレー，アニック
コルツェヴスキ，サビーネ
ムスジンスキィ−バージー，ドーン・マリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004534758A publication Critical patent/JP2004534758A/ja
Publication of JP2004534758A5 publication Critical patent/JP2004534758A5/ja
Application granted granted Critical
Publication of JP4056887B2 publication Critical patent/JP4056887B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2002589488A 2001-05-14 2002-05-06 １−オキサ−３，９−ジアザ−スピロ［５．５］ウンデカン−２−オン誘導体およびそのニューロキニン受容体拮抗剤としての使用 Expired - Fee Related JP4056887B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (3)

Publication Number Publication Date
JP2004534758A JP2004534758A (ja) 2004-11-18
JP2004534758A5 JP2004534758A5 (https=) 2005-08-25
JP4056887B2 true JP4056887B2 (ja) 2008-03-05

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589488A Expired - Fee Related JP4056887B2 (ja) 2001-05-14 2002-05-06 １−オキサ−３，９−ジアザ−スピロ［５．５］ウンデカン−２−オン誘導体およびそのニューロキニン受容体拮抗剤としての使用

Country Status (17)

Country Link
US (1) US6599900B2 (https=)
EP (1) EP1390372B1 (https=)
JP (1) JP4056887B2 (https=)
KR (1) KR100618063B1 (https=)
CN (1) CN1264847C (https=)
AR (1) AR033631A1 (https=)
AT (1) ATE401333T1 (https=)
AU (1) AU2002342238B2 (https=)
BR (1) BR0209604A (https=)
CA (1) CA2447329C (https=)
DE (1) DE60227657D1 (https=)
DK (1) DK1390372T3 (https=)
ES (1) ES2310206T3 (https=)
MX (1) MXPA03010321A (https=)
PT (1) PT1390372E (https=)
WO (1) WO2002092604A1 (https=)
ZA (1) ZA200308535B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863854B1 (ko) 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ｃｃｒ5 수용체 조절제
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
KR101355064B1 (ko) * 2005-03-03 2014-01-24 얀센 파마슈티카 엔.브이. 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010522707A (ja) 2007-03-29 2010-07-08 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Also Published As

Publication number Publication date
CN1507449A (zh) 2004-06-23
CA2447329C (en) 2009-07-28
AU2002342238B2 (en) 2007-01-25
BR0209604A (pt) 2004-03-23
KR20030094405A (ko) 2003-12-11
CN1264847C (zh) 2006-07-19
MXPA03010321A (es) 2004-02-17
AR033631A1 (es) 2003-12-26
KR100618063B1 (ko) 2006-08-30
WO2002092604A1 (en) 2002-11-21
ZA200308535B (en) 2005-01-31
DK1390372T3 (da) 2008-09-15
JP2004534758A (ja) 2004-11-18
DE60227657D1 (de) 2008-08-28
EP1390372B1 (en) 2008-07-16
ES2310206T3 (es) 2009-01-01
EP1390372A1 (en) 2004-02-25
PT1390372E (pt) 2008-08-25
ATE401333T1 (de) 2008-08-15
US20030004163A1 (en) 2003-01-02
US6599900B2 (en) 2003-07-29
CA2447329A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1292596B1 (en) 1,3,8-triaza-spiro¬4,5 decan-4-one derivatives as neurokinin receptor antagonists
TW202206429A (zh) 雜環ｇｌｐ—１促效劑
JP4488743B2 (ja) ピペリジン誘導体
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
JPH10511381A (ja) スピロケタール誘導体、該誘導体を含有する組成物、及び該誘導体の治療薬としての使用
KR20070063562A (ko) 치환 디피페리딘 ｃｃｒ２ 길항제
JP4056887B2 (ja) １−オキサ−３，９−ジアザ−スピロ［５．５］ウンデカン−２−オン誘導体およびそのニューロキニン受容体拮抗剤としての使用
CA3048376A1 (en) Bmp-signal-inhibiting compound
JPH09507500A (ja) ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬
BR112020018983A2 (pt) Inibidores de canal receptor de potencial transitório de oxadiazol
AU2001267513A1 (en) 1,3,8-triaza-spiro'4,5!decan-4-one derivatives as neurokinin receptor antagonists
WO1999032489A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
PL185029B1 (pl) Nowa 1-(1,2-dwupodstawiona-piperydynylo)-4-podstawiona pochodna piperazyny, kompozycja farmaceutyczna, sposób wytwarzania kompozycji farmaceutycznej i sposób wytwarzania 1-(1,2-dwupodstawionej-piperydynylo)-4-podstawionej pochodnej piperazyny
WO1999032481A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
DE602004007658T2 (de) Indolderivate mit verbesserter antipsychotischer wirkung
HU224703B1 (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-0-tolyl-pyridin-3-yl)-isobutyramide, process for producing it, and pharmaceutical compositions containing it
JP3287577B2 (ja) １，２，３，４―テトラヒドロ―ベンゾフロ［３，２―ｃ］ピリジン誘導体
AU2002342238A1 (en) 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
JP2001515899A (ja) テトラヒドロガンマ−カルボリン類
EA010312B1 (ru) Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов
MX2007000694A (es) Combinacion de un inhibidor selectivo de reabsorcion de noradrenalina y un inhibidor.
WO2021175848A1 (en) Alpha-methyl-substituted diazabicyclo[4.3.1] decane derivates for treatment of psychiatric disorders
DE69707104T2 (de) Spiro-ketal derivate und ihre verwendung als therapeutische wirkstoffe
WO1999032486A1 (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2008521771A (ja) 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071212

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101221

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees